TABLE 2.
Baseline lipid parameters
| Lipids (mg/dl) | Placebo (N = 11) | Mipomersen (N = 10) | FHBL (N = 6) |
|---|---|---|---|
| LDL-C | 155 ± 31 | 155 ± 37 | 46 ± 18 |
| VLDL-C | 18 ± 6 | 20 ± 7 | 8 ± 3 |
| Non-HDL-C | 173 ± 35 | 175 ± 38 | 54 ± 19 |
| HDL-C | 46 ± 10 | 47 ± 13 | 56 ± 6 |
| TC | 219 ± 29 | 222 ± 37 | 110 ± 20 |
| TG | 91 (52–133)a | 102 (51–166)a | 32 (23–63)a |
| Apo A1 | 144 ± 19 | 149 ± 26 | 156 ± 20 |
| Apo B | 124 ± 24 | 131 ± 29 | 35 ± 10 |
| Lp(a) | 50 ± 62 | 78 ± 74 | 22 ± 22 |
Data are presented as the mean ± standard deviation. Apo, apolipoprotein; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; LP(a), lipoprotein (a); TC, total cholesterol TG, triglycerides; VLDL-C, VLDL-cholesterol.
a
Data are presented as the median (min–max).